Trial Profile

A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CC 95775 (Primary) ; Azacitidine
Indications Acute myeloid leukaemia; B-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors FORMA Therapeutics; Novo Nordisk

06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
25 Jun 2019 Status changed from recruiting to completed.
14 Feb 2018 Azacitidine drug has added in the study hence treatment arms and patients numbers are increases. study design has also changed from single assignment to parallel.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com